Seer’s Proteomics Tech Hits 100 Peer-Reviewed Milestone, Validating Large-Scale Deep Proteomics — Seer, Inc.

Event summary

Seer’s Proteograph® Product Suite has been cited in over 100 peer-reviewed scientific publications across genetics, aging, disease biology, and biomarker discovery.
The technology combines engineered nanoparticles with mass spectrometry to enable deep, unbiased proteomic analysis at scale.
Key studies include a Nature Genetics paper profiling 1,400 British South Asian participants, identifying 3,430 proteins not covered by leading affinity platforms.
Another study in Nature Genetics used Proteograph to improve the accuracy of genetic associations with protein biology, distinguishing true biological changes from measurement artifacts.
Research presented at the 2026 HUPO World Congress will further validate the technology’s applications.

The big picture

Seer’s milestone underscores a shift in proteomics research, where deep, unbiased analysis is now feasible at scale. This development aligns with broader industry trends toward precision medicine and AI-driven biological discovery, positioning Seer as a key player in the proteomics space. The validation of its technology through peer-reviewed publications strengthens its competitive edge, particularly as researchers seek more comprehensive and reproducible proteomic data.

What we're watching

Adoption Pace: The pace at which Proteograph technology is integrated into large-scale research studies will determine its long-term market penetration.
AI Synergy: How Seer’s deep proteomics data will enhance AI-driven biological research, given the growing demand for high-quality, large-scale datasets.
Clinical Translation: Whether the insights generated from Proteograph-enabled research can be translated into clinical applications, potentially expanding the technology’s commercial potential.